Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy. Indeed, modulating immune inhibitory pathways has been considered an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzone, Roberta, Zwergel, Clemens, Mai, Antonello, Valente, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450222/
https://www.ncbi.nlm.nih.gov/pubmed/28572863
http://dx.doi.org/10.1186/s13148-017-0358-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450222/
https://www.ncbi.nlm.nih.gov/pubmed/28572863
http://dx.doi.org/10.1186/s13148-017-0358-y

Ejemplares similares